Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.50    1.50 (2.14%)
Bid:
71.00
Ask:
72.00
Spread: 1.00 (1.408%)
Market Cap: £325.40m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Holding(s) in Company

30 May 2014 16:37

RNS Number : 5167I
Avacta Group PLC
30 May 2014
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Avacta Group Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Baillie Gifford & Co

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

29 May 2014

6. Date on which issuer notified:

30 May 2014

7. Threshold(s) that is/are crossed orreached: vi, vii

5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

Ordinary Shares

GB0033519546

Below 5%

Below 5%

254,545,450

254,545,450

5.12%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

254,545,450

5.12%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

In the narrative below, the figures in [ ] indicate the amount of voting rights and the percentage held by each controlled undertaking where relevant.

 

Baillie Gifford & Co, a discretionary investment manager, is the parent undertaking of an investment management group.

 

Its wholly-owned subsidiary undertaking Baillie Gifford & Co Limited [163,636,361:3.29%] is an OEIC Authorised Corporate Director and Unit Trust Manager which has delegated its discretionary investment management role to Baillie Gifford & Co.

 

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Gillian Wright

15. Contact telephone number:

 

0131 275 3041

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFMGFKKGDGDZM
Date   Source Headline
5th May 20157:01 amRNSIssue of Equity
28th Apr 20157:00 amRNSHalf Yearly Report
8th Apr 20157:00 amRNSNotice of Results
23rd Mar 20157:00 amRNSDrug discovery partnership
23rd Mar 20157:00 amRNSIssue of Equity
12th Feb 20157:00 amRNSSale of Optim Trade and Assets
9th Feb 20157:00 amRNSAffimer Development Contract with Protatonce
23rd Jan 20152:31 pmRNSResult of AGM
23rd Jan 20157:00 amRNSTrading Statement
16th Jan 20157:00 amRNSCommercial Partnership in the Agri-bio Market
6th Jan 20157:00 amRNSIssue of Equity
22nd Dec 20147:00 amRNSPosting of Annual Report & Accounts and AGM Notice
16th Oct 20147:00 amRNSFinal Results
30th Sep 20147:00 amRNSAffimer On-line Catalogue Launch
29th Sep 20147:00 amRNSInvestor Briefing
22nd Sep 20147:00 amRNSAppointment of a Senior Executive
4th Aug 20147:00 amRNSNew OPTIM Software and Hardware
1st Aug 20147:00 amRNSPre Close Trading Update
15th Jul 20147:00 amRNSMajor Japanese Distributor Signed
13th Jun 201411:04 amRNSHolding(s) in Company
2nd Jun 20141:04 pmRNSHolding(s) in Company
2nd Jun 20147:00 amRNSAvacta Secures Funding Award
30th May 20144:37 pmRNSHolding(s) in Company
30th May 20142:52 pmRNSHolding(s) in Company
29th May 20144:21 pmRNSHolding(s) in Company
28th May 20147:00 amRNSAvacta Life Sciences Exhibits Affimers at PEGS
23rd May 201412:53 pmRNSResult of General Meeting
21st May 20145:36 pmRNSHolding(s) in Company
14th May 20147:00 amRNSIssue of Equity
9th May 20144:19 pmRNSDirector's dealing
9th May 20147:00 amRNSAvacta Announce Collaboration with UbiQ Bio BV
7th May 20147:00 amRNSConditional Placing
23rd Apr 20147:00 amRNSInterim Results
14th Apr 20147:00 amRNSAvacta Launch Pancreatitis Test for Dogs
20th Mar 20147:00 amRNSAffimers : Technical and Commercial Update
11th Mar 20147:00 amRNSNotice of Interim Results
24th Feb 20147:00 amRNSDirectors Dealings
5th Feb 20147:00 amRNSNew Board Appointment
4th Feb 20149:29 amRNSHolding(s) in Company
3rd Feb 20147:00 amRNSAvacta Initiates Collaboration with University
28th Jan 20147:00 amRNSAvacta Life Sciences Launches Affimers Web Site
24th Jan 20142:57 pmRNSResult of AGM
24th Jan 20147:00 amRNSAGM Statement
20th Jan 20147:00 amRNSIssue of Equity
13th Jan 20147:00 amRNSInvestor teach-in
23rd Dec 20132:59 pmRNSNotice of AGM and Report and Accounts
23rd Dec 20137:00 amRNSBoard Appointment
27th Nov 201310:01 amRNSNew Canine Lymphoma Blood Test Launched
1st Nov 20137:00 amRNSIssue of Equity
24th Oct 20137:00 amRNSPreliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.